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Summary of Genetic Clinic Population: 1973-1977
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defects, diabetes, uncomplicated cleft lips and/ or palate, clubfeet, seizures, and certain patients with familial mental retardation that could not be otherwise
classified. Patients falling into the other categories
included individuals with multiple malformations or
repeated abortions with normal chromosomes and no
other definite causes, or patients with psychomotor
retardation of unknown or environmental etiology.
During the year 1976 (Figure), patients came
from all parts of the state either to the Genetic Counseling and Amniocentesis Clinics or for diagnostic
karyotypic analysis. This pattern of referrals is
largely a result of the central location of the Clinic in
a large urban area.
Referrals to Genettc Coooseing Program

sample included pa tients with D and E trisomy, the
cri du chat syndrome, Turner syndrome, Klinefelter
syndrome, the 4p-syndrome, and a variety of structural rearrangements.
Patie.nts classified as having multifactorial diseases included individuals with midline neurologic

from Virginia's Health C•e Districts, 1976

Figure-Pattern of referrals to Genetic Counseling Program
from Virginia's health care district, 1976.
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and lay communities. The desirability of initiating
population screening progr.ams is an example of one
such issue that has engendered considerable confusion concerning its intent-so much so that the
National Academy of Sciences recently reviewed this
subject and in 1975 published a book entitled, Genetic Screening-Programs, Principles and Research. 1

MAMUNES: SCREENING FOR GENETIC DISEASE
This presentation will describe the four major forms
of population screening for genetic disease and, from
the Virginia experience with some of them, demonstrate their strengths and shortcomings.
Most readers are already aware of programs to
screen for disorders such as hypertension, diabetes,
cervical cancer, glaucoma, and other diseases. These
programs were established with the idea that they are
inexpensive, can be detected by a simple test, and that
effective treatment is available. The same principles
apply to the four major types of population screening
programs for genetic disorders .
I. Carrier detection. Almost all persons are believed to carry approximately four lethal or deleterious recessive genes; however, their existence is
usually never known unless the spouse has the same
gene, in which case there is a one-in-four chance that
each child will inherit a "double dose" of the abnormal gene and develop the disorder. Fortunately, most
serious recessive diseases are rare, but there are twosickle cell disease and Tay-Sachs disease-which are
especially prevalent in specific subpopulations and
for which simple, reliable, and relatively inexpensive
carrier tests are available. Screening programs for
detection of heterozygotes (carriers) in both disorders
have existed in Virginia for at least five years. Elsewhere in this issue experience with the Medical College of Virginia Sickle Cell Program is described.
Tay-Sachs disease affects approximately 1 : 4,000
Ashkenazi Jewish births and is invariably lethal by
the fourth year because of the abnormal accumulation of a sphingolipid, ganglioside G M 2 , in the central nervous system. 2 Hexosaminidase A, the enzyme
which is necessary for the normal degradation of this
material, is inactive in these patients and is present in
only approximately 50% of normal activity in the
serum, white blood cells, and other tissues of carriers.
Women who are at risk to give birth to such children
can therefore be identified before pregnancy. If both
parents are carriers, an amniocentesis performed in
the second trimester can determine the enzyme status
of the fetus. If Tay-Sachs disease is found, the parents
then have the option to terminate the pregnancy to
avert the birth of an affected child.
Measurement of the serum enzyme level is not in
itself technically difficult, but so many factors affect
its activity (for example, pregnancy, cleanliness of
test tubes in which blood is collected, the time during
which the serum remains at room temperature before
freezing, storage temperature prior to testing, medications taken by patient) that it is not practical for
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the local physician to forward blood to the testing
laboratory from patients wishing their carrier status
determined. Although with special precautions and
arrangements, testing of remote patients can be done,
a more desirable procedure is to schedule periodic
mass community testing at various sites. These mobile screening clinics not only obviate the abovementioned difficulties but they offer a better opportunity to ensure that tested individuals have been properly informed regarding the purpose and possible
consequence of the testing. Because this concept of
carrier testing is a new one, the most difficult aspect
of such screening is to educate the public in the
importance of voluntary participation . Most people
will not have heard of the disease, and what is more
significant they find it difficult to believe that they
have a 1: 30 chance of being carriers. A second obstacle to successful screening is the lack of funding for
such programs. After initial equipment cost outlay,
the cost for the Tay-Sachs test averages $7 .00 ±
$2.00, depending on the volume of tests, per individual. The MCV Tay-Sachs Screening Program, operative since 1972, was fortunate to obtain initial support from the Virginia State Department of Health
and local Jewish community organizations so that it
has been able to offer the test without a fixed charge
to tested persons .
As a result of Virginia screening, over 3,700 Jewish persons have been tested at sites in their own cities
of Richmond, Norfolk, Newport News , Roanoke,
and Fredericksburg; the metropolitan northern Virginia cities have used testing sites in southern Maryland and Washington, D.C., provided by Johns Hopkins Hospital. Over 100 carriers have been identified
and counseled, but surprisingly no carrier couple has
thus far been found. A full 25% of all adult Jewish
people in these cities have been tested. In almost all of
the more populous United States cities where testing
has been offered for several years, no more than 5%
to 10% have appeared for this voluntary test. Clearly,
a significant educational effort is needed on two
fronts: to convince governmental agencies of the need
for appropriate funding for these programs and to
inform the public regarding the concept of disease
prevention by carrier detection. Support of these efforts is needed soon, for in the very near future carrier detection tests for other more common recessive
diseases, such as cystic fibrosis, promise to be available.
Phenylketonuria (PK U) carrier detection is a
second test that we currently provide, using a dis-
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criminant function, based on serum amino acid levels, that we have recently developed in our laboratory. In this case, since there is no ethnic group in
which the gene has a high incidence, we offer the test
to the collateral relatives of all new cases of PK U that
come to our attention.
2. Antenatal screening. There is a ~mall but
clearly definable group of pregnant women ,for whom
screening is indicated because of their substantially
increased risk of bearing a child with a genetic disorder. The Antenatal Testing Program, jointly administered by\the Departments of Obstetrics and Gynecology, Human Genetics , and Pediatrics, is
discussed elsewhere in this issue.
3. Mass neonatal screening. The prototype in
this level of screening is the Guthrie test to detect
PK U, an assay performed on a dried blood spot
obtained in the first week of life. Virginia State law
established the program in 1966 and made it the joint
responsibility of the parent and / or the physician to
provide that the neonate be screened for this condition. Since that time, four to five children with PK U
per year (approximately I: 16,000 births) have been
discovered and mental retardation averted by maintaining them on a phenylalanine-restricted diet for
the first six to seven years of life. The cost for early
screening and treatment is approximately one tenth
the cost of special education or institutionalization of
late-diagnosed, retarded PK U children .
With the demonstrated success of the PK U
screening program , many states and foreign countries
have established screening programs for other disorders using the same blood spots. The grafting of
these additional programs onto an already-existing
one and the availability of a machine to handle the
blood-spotted filter paper have minimized their cost.
The decision of which additional disorders to screen
should relate to the following major factors:
a)
b)
c)
d)

frequencyofthedisorder,
severity of the untreated disorder,
simplicity and sensitivity of the test, and
availability of treatment to ameliorate or prevent the disorder.

Under the above considerations, hypothyroidism (by
radioimmunoassay of thyroxine), galactosemia (by
bacterial inhibition assay) , and several aminoacidopathies including homocystinuria, maple syrup
urine disease (MSUD), and histidinemia (all also by
bacterial inhibition assay) qualify .3 Because of its
frequency ( I : 6,000) and ease of treatment, and the

severity of the mental retardation that ensues due to
delayed diagnosis, hypothyroidism warrants immediate development of screening programs .4 •5 Therefore,
a neonatal hypothyroid screening program in Virgini a is planned for 1978. It is hoped that additional
programs for galactosemia and other aminoacidopathies will also be initiated soon.
The spectrum of metabolic disorders screened
can be considerably expanded if the urine of two- to
three-week old infants is ,aiso tested by various simple
chromatographic and high-voltage electrophoretic
techniques . Such a program , using specimens collected on filter paper at home by the parent and
mailed to the central laboratory performing the
blood tests, has already been in effect for several
years in M assachusetts 6 and several other states. This
procedure also serves as a follow-up test to detect
neonates with false-negative blood results for the
previously mentioned a minoacidopathies, including
PKU .
Except for the PKU program, testing for other
disorders in Virginia and most other states is and will
be voluntary. An advisory committee of consumers,
experts in metabolic disease, geneticists, laboratory
personnel , clergy, and ethicists is clearly needed to
serve as an advisory body to determine the propriety
and mode of administration of these proliferating
programs.
4. Urine metabolic screening. While the total incidence of ihborn errors of metabolism is probably
no greater than I: 5,000, these disorders are more
often seen in children with mental retardation , seizures, hepatosplenomegaly, recurrent or persistent
acidosis, failure to thrive, or unusual odor to urine or
sweat. Where the etiology of any of these conditions
is unclear, one of the inborn errors of metabolism
must be considered; therefore, a variety of simple
tests on a random urine specimen is recommended to
screen for over 30 such disorders of amino acid,
mucopolysaccharide, and carbohydrate metabolism. 7
At the pediatric metabolic laboratory the following
tests are routinely performed weekly on a 20 ml acidified random urine specimen received by mail: a)
ferric chloride and dinitrophenylhydrazine tests to
detect the alpha-keto acid excesses found in PKU,
tyrosinemia , MSUD , and histidinemia; b) silver nitroprusside test for homocystinuria; c) Benedict's
tablet for reducing substances; d) gross turbidity test
for mucopolysaccharidoses; e) isatin spot test for the
iminoaciduria of praline or hydroxyproline excess; f)
nitrosonaphthol test for tyrosinosis; and g) high-volt-
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age separation of all urinary amino acids to detect
any excesses. Although the yield of newly diagnosed
inborn errors by this screening program is small,
those few cases detect~d are important because they
may le;id to a specific diagnosis that permits a prognosis, a recurrence risk for other family members,
and counseling about the possibility of treatment or
prenatal diagnosis for future pregnancies.
Clearly, genetic screening programs are an important component of the primary care physician's
efforts in preventive medicine. Participation in and
support of these programs is therefore strongly
urged.
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In 1968, a program of screening for sickle trait
carriers was begun as part of the work of the Hematology Division, Department of j'vtedicine, at the
Medical College of Virginia. It was felt that sickle cell
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anemia was more of a public health problem than
was generally recognized, and in addition to institutipg screening and education programs, data were collected to document the rela tive neglect of the problem.
A survey of the Cjty of Richmond was conducted to ascertain the level of awareness among

